The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND/AIMS: While substantial prior research has evaluated the psychometric properties of the 12-item Concise Health Risk Tracking-Self Report (CHRT-SR12), a measure of suicide propensity and suicidal thoughts, no prior research has investigated its factor structure, sensitivity to change over time, and other psychometric properties in a placebo-controlled trial of antidepressant medication, nor determined whether symptoms change throughout treatment. METHODS: Participants in the multi-site Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study ( n=278) provided data to evaluate the factor structure and sensitivity to change over time of the CHRT-SR12 through eight weeks of a clinical trial in which participants received either placebo or antidepressant medication (sertraline). RESULTS/OUTCOMES: Factor analysis confirmed two factors: propensity (comprised of first-order factors including pessimism, helplessness, social support, and despair) and suicidal thoughts. Internal consistency (α's ranged from 0.69-0.92) and external validity were both acceptable, with the total score and propensity factor scores significantly correlated with total scores and single-item suicidal-thoughts scores on the self-report Quick Inventory of Depressive Symptoms and the clinician-rated 17-item Hamilton Rating Scale for Depression. Through analyzing CHRT-SR12 changes over eight treatment weeks, the total score and both the factors decreased regardless of baseline suicidal thoughts. Change in clinician-rated suicidal thoughts was reflected by change in both the total score and propensity factor score. CONCLUSIONS/INTERPRETATION: These results confirm the reliability, validity, and applicability of the CHRT-SR12 to a placebo-controlled clinical trial of depressed outpatients receiving antidepressant medication.

Full Text

Duke Authors

Cited Authors

  • Trombello, JM; Killian, MO; Grannemann, BD; Rush, AJ; Mayes, TL; Parsey, RV; McInnis, M; Jha, MK; Ali, A; McGrath, PJ; Adams, P; Oquendo, MA; Weissman, MM; Carmody, TJ; Trivedi, MH

Published Date

  • February 2019

Published In

Volume / Issue

  • 33 / 2

Start / End Page

  • 185 - 193

PubMed ID

  • 30652941

Pubmed Central ID

  • PMC6379122

Electronic International Standard Serial Number (EISSN)

  • 1461-7285

Digital Object Identifier (DOI)

  • 10.1177/0269881118817156


  • eng

Conference Location

  • United States